Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707469 · ClinicalTrials.gov registry record · Phase 3
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,606
- Enrollment target
NCT04707469: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT04707469 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,606 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04707469, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,606 participants
- Enrollment target
Study Summary
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.
Primary Outcome
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
Interventions
- DRUG Oral semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,606 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2023-03-08 |
| Phase | Phase 3 |
What the finished NCT04707469 record still lists
NCT04707469 is an interventional study that assigns participants to a tested intervention. Its 1,606 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 1 intervention - of which Oral semaglutide is the first listed.
NCT04707469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04707469 about?
NCT04707469 is a clinical study titled "Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes". This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14...
What is the current status of trial NCT04707469?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,606 participants. The study started on 2021-01-15. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT04707469?
The interventions under investigation include: Oral semaglutide (DRUG).
Who is sponsoring clinical trial NCT04707469?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04707469's enrollment target sits among peer trials
1,606 142nd of 2000 higher than 1,859 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI